EFFECTS OF DESIDUSTAT Vs DAPAGLIFLOZIN IN CARDIO RENAL ANEMIA SYNDROME-A RANDOMISED CONTROL TRIA
- Conditions
- Health Condition 1: I501- Left ventricular failure, unspecified
- Registration Number
- CTRI/2024/01/062083
- Lead Sponsor
- SRM COLLEGE OF PHARMACY
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
•Patient of both genders aged between 35-65yr
•Patients who have a known history of Acute/Chronic Renal failure(Non Dialysis dependent)
•Patients with a known history or newly diagnosed with any cardiovascular events (Heart failure ,atherosclerosis,MI,)
•Patients with mildly reduced left ventricular ejection fraction(upto 40%)
• Patients with baseline hemoglobin of 8-11g/dl
•Patients willing to sign the Informed Consent Form
Patients who are on erythropoietin stimulating agents therapy
(Epoetin and Darbepoetin) prior to enrollment in the study.
Patients with a history of red blood cell transfusion prior to
enrollment
Patients with e GFR <30ml/min
Pregnant and lactating women
History of Autoimmune hemolytic anemia, Idiopathic
Thrombocytopenic Purpura (ITP) or Thalassemia.
Patients with any GI/small intestine related mal absorption
syndromes
History of Stroke or intracranial haemorrhage
History of hepatic impairment
Patients with symptoms of hypotension or a systolic blood
pressure of less than 95 mm Hg
Patients who are not ready for regular follow ups
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method